Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2Carcinoma, Merkel Cell 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1

Interventions

pembrolizumab 29avelumab 21Nivolumab 20Ipilimumab 10Radiotherapy 9Cyclophosphamide 9atezolizumab 8cemiplimab 7fludarabine 6Specimen Handling 6durvalumab 5aldesleukin 5Radiation 5Magnetic Resonance Spectroscopy 5Interleukin-2 5Biopsy 5talimogene laherparepvec 4ALT-803 4poly ICLC 3Radiosurgery 3Etoposide 3Cisplatin 3Carboplatin 3CTLA-4 Antigen 3Bevacizumab 3prednylidene 2lutetium Lu 177 dotatate 2fludarabine phosphate 2domatinostat 2deltacortene 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × domatinostat × Clear all
NCT04393753 2024-05-08

MERKLIN2

4SC AG

Phase 2 Completed
19 enrolled
Dermatologic

Carcinoma, Merkel Cell

NCT04874831 2021-11-18

Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)

4SC AG

Phase 2 Withdrawn
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡